These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

724 related items for PubMed ID: 15631624

  • 21. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
    Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D.
    J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
    [Abstract] [Full Text] [Related]

  • 22. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
    Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M.
    Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 24. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.
    Depress Anxiety; 2008 Jul; 25(3):182-9. PubMed ID: 17311303
    [Abstract] [Full Text] [Related]

  • 26. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [Abstract] [Full Text] [Related]

  • 27. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG.
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [Abstract] [Full Text] [Related]

  • 28. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC.
    Depress Anxiety; 2010 Aug; 27(1):12-8. PubMed ID: 20013987
    [Abstract] [Full Text] [Related]

  • 29. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Hann D, Marangell LB.
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [Abstract] [Full Text] [Related]

  • 30. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo.
    Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S.
    Curr Med Res Opin; 2012 Jan; 28(1):41-8. PubMed ID: 22126422
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment.
    Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, Ball S, Swindle R.
    J Psychiatr Res; 2008 Oct; 42(12):1042-9. PubMed ID: 18221755
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV.
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [Abstract] [Full Text] [Related]

  • 35. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
    Fava M, Wiltse C, Walker D, Brecht S, Chen A, Perahia D.
    J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
    [Abstract] [Full Text] [Related]

  • 36. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.
    Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, Wohlreich MM.
    Ann Clin Psychiatry; 2007 Mar; 19(3):187-95. PubMed ID: 17729021
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S, Desaiah D, Marechal ES, Santini AM, Podhorna J, Guelfi JD.
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [Abstract] [Full Text] [Related]

  • 38. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.
    Depress Anxiety; 2002 Aug; 16(1):4-13. PubMed ID: 12203668
    [Abstract] [Full Text] [Related]

  • 39. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.